Navigation Links
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Date:11/11/2008

- Milestone Marks the First Time a European Patient with Active Celiac Disease has Enrolled in a Clinical Trial for an Investigational Medication

from Alba Therapeutics -

BALTIMORE, Nov. 11 /PRNewswire/ -- Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while assessing improvement in the clinical signs and symptoms of celiac disease.

"These are decisive times for our desire to one day be able to offer our celiac patients a treatment that allows them to live more normal lives," said Dr. Gemma Castillejo, MD, a pediatric gastroenterologist and principal investigator in the study. Dr. Castillejo, a leading European celiac expert from the Sant Joan de Reus University Hospital in Reus, Spain added, "I believe this clinical trial has the potential to be a turning point in the search for treatments for celiac disease."

"This is a major milestone for the celiac community in Europe," stated Francisco Leon, MD, PhD, Vice President, Clinical Development and Medical Affairs of Alba. "This is Alba's sixth human trial with larazotide acetate, and we are excited to be advancing our investigational program for larazotide acetate in this important region of the world."

About Celiac Disease

Celiac disease is an inherited autoimmune disorder where gluten has been identified as the environmental trigger of the disea
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
3. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
6. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
7. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
8. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
9. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...CISCO, Calif., Nov. 9 An...on November 5, 2009, it received a letter from The...he Nasdaq Hearing Panel has granted Anesiva,s requ...ket subject to the condition that Anesiva shall ha...roposed merger (the "Merger") contemplated by the ...
(Date:11/7/2009)...la., Nov. 7 Patients reported C1-e...tive therapy in treating acute swelling attacks at...etic disorder, according to data presented today a...p; Immunology (ACAAI) Annual Meeting. The results ...cted in parallel with the ongoing, prospective, op...
(Date:11/6/2009)... WASHINGTON, Pa., Nov. 6 In consul...(FDA), McNeil Consumer Healthcare, Division of McN... a limited number of product lots of TYLENOL®... distinctive red EZ-OPEN CAP. McNeil is initiating...smell or taste associated with these lots that led...
Breaking Medicine Technology:Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine 28TM 29 For Prostate Conditions With Start Up of Phase 2 BPH Trial 54732 1Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine 28TM 29 For Prostate Conditions With Start Up of Phase 2 BPH Trial 54732 2Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine 28TM 29 For Prostate Conditions With Start Up of Phase 2 BPH Trial 54732 3Abnormal Protein May Signal Pancreatic Cancer 54730 1Abnormal Protein May Signal Pancreatic Cancer 54730 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 9609 1Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 9609 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 9609 3
...th Lovenox(R) (enoxaparin sodium injection) were a...l within 90 days-, BRIDGEWATER, N.J., Dec 10 San... that demonstrated total hospital,direct medical c...$550 per,patient when they were treated with the u...actionated heparin (UFH) with 97.3% of LMWH patien...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today r...r,of fiscal 2008., The company recorded a net los...c and diluted common share, for the fiscal quarter...ion, or $0.05 per basic and diluted,common share, ...administrative expenses increased by approximately...
Other Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:11/9/2009)...N, Nov. 9 Today,s drama...gs us one step closer to meaningful health care re...th Care for America Act makes health care more acc...y enhancing coverage, promoting preventive care an...lso serves as a sober reminder of the tremendous a...
(Date:11/9/2009)... New Health Care Reform Bill, The Afford...he House Of Representatives Saturday Night, and Is...bama by the End of the Year with Absolute Confiden...alist Certification Class Specifically for the Com...% of Americans , Hanover ...
(Date:11/9/2009)... Only 5 percent of seniors have changed ...avings, better service and improved coverage among...llment season nears , , B...ly 5 percent of seniors have changed their Medicar...y (16 percent) report they are likely to or are co...
(Date:11/9/2009)...inds that women treated for breast cancer are at h... breasts. Published in the December 15, 2009 issue...can Cancer Society, the study,s results indicate t...benefit from additional therapies following surger...e that women with dense breast tissue are at incre...
(Date:11/8/2009)...HIA, Nov. 8 The America...evention and wellness provisions in the health ref...th passage of this bill, the House takes important...tant insurance reforms and moving our health syste...e that focuses on keeping people healthy," said Ge...
Breaking Medicine News(10 mins):Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 2Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 3Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 4Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 5Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Breast density associated with increased risk of cancer recurrence 2Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2
...The U-C-L-A Medical Center, in Los Angeles is witn...on after a heart transplant. His twin, also in nee...// Nick and Nate Draper, the twin brothers wer...enter. According to the Doctors, Nick Draper...
... study led by Ronald Hines, professor of pediatric...ult and children have very different drug metaboli...s (enzymes) in their body for the processing of th...e young. This plays a vital role because certa...
...ior doctor has by the means of BMJ raised a seriou...alization purposes. // This has come after n... approved and thereafter recalled after three mont... Drug Administration in 2004 on the basis of short...
...ses like diabetes, cancer and heart attack that ar...s could cause much strain to the Indian economy, /...ost by 2015, according to estimates by World Healt...s Robert Beaglehole, director of NCD, WHO. H...
...us concerns have been raised regarding the safety ...ports of increased risk of autism // in children ...st mumps, measles and rubella. Currently, ch...nt vaccine preventable diseases. The government ha...
...ed River Valley Water Supply Project's key agenda ...stern North Dakota, especially heavily populated a...ronmental groups are up in arms against this propo...eels that a task of such a magnitude , interbasin ...
Other Medicine News:
Moody Curved Fixation Forceps
Lindstrom Curved Pierce Forcep
Green Fixation Forceps
Kuhnt Fixation Forceps
Medicine Products: